Scientists Pinpoint Obesity Gene

Wednesday, 12 Mar 2014 04:58 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Scientists who identified a gene that appears to be strongly linked with obesity say their discovery could help efforts to find drug treatments for obesity and diabetes.

"Our data strongly suggest that [the gene] IRX3 controls body mass and regulates body composition," study senior author Marcelo Nobrega, an associate professor of human genetics at the University of Chicago, said in a university news release.

Although the research showed an association between the gene and obesity, it did not prove a cause-and-effect link.

The IRX3 gene was first pinpointed through an analysis of about 150 brain samples from people of European ancestry, according to the study, which was published online March 12 in the journal Nature.

Editor’s Note: How Long Should You Use Cholesterol-Lowering Drugs? Doctor Answers

To verify the role of IRX3 in obesity, the researchers created mice without the gene and found that they weighed about 30 percent less than normal mice. Much of this weight difference was due to reduced amounts of fat in the mice without the IRX3 gene.

"These mice are thin. They lose weight primarily through the loss of fat, but they are not runts," study co-author Chin-Chung Hui, a professor of molecular genetics at the University of Toronto, said in the news release.

"They are also completely resistant to high-fat diet-induced obesity," Hui said. "They have much better ability to handle glucose, and seem protected against diabetes."

The researchers also found that mice with altered function of the IRX3 gene in the hypothalamus -- the part of the brain that controls eating and energy output -- were as lean as mice that lacked the gene.

This suggests that the gene's activity in the hypothalamus controls body mass and composition in mice, and that genetic predisposition to obesity is wired in the brain, according to the study authors.

Findings from animal studies often can't be replicated in human trials, however.

Previous research has suggested that mutations in a gene called FTO play a strong role in determining obesity risk in people. But this study found that the obesity-related mutations in FTO interact with IRX3, and that FTO itself has only a minor effect on obesity risk.

Editor’s Note: How Long Should You Use Cholesterol-Lowering Drugs? Doctor Answers

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Plant-Based Vaccines Challenge Big Pharma Dominance

Wednesday, 01 Oct 2014 08:07 AM

Two tiny companies are preparing to challenge some of the world's largest drugmakers in the battle for dominance in the  . . .

Irritable Bowel Drug Shows Promise in Trial

Wednesday, 01 Oct 2014 07:57 AM

Ardelyx Inc. said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of . . .

Ebola in the US: What You Need to Know

Wednesday, 01 Oct 2014 07:50 AM

U.S. health officials have warned for months that someone infected with Ebola could unknowingly carry the virus to this  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved